ACELYRIN, INC.

The momentum for this stock is not very good. ACELYRIN, INC. is not very popular among insiders. Tradey thinks it is not wise to invest in ACELYRIN, INC..

News

Acelyrin announces PoC data from Phase 1/2 trial of lonigutamab

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

ACELYRIN, INC. to Participate in Upcoming Investor Conferences

Globe Newswire LOS ANGELES, Aug. 22, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative...\n more…

Acelyrin price target lowered by $7 at Morgan Stanley, here's why

Acelyrin Cuts Workforce, Deprioritizes Former Lead Drug Izokibep

Benzinga Acelyrin reports promising Phase 3 results for izokibep in hidradenitis suppurativa, announces a strategic focus on lonigutamab.\n more…

Acelyrin just downgraded at H.C. Wainwright, here's why

Companies Like Acelyrin (NASDAQ:SLRN) Are In A Position To Invest In Growth

Simply Wall St We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...\n more…